Effects of daily chlorpromazine administration on behavioural and physiological parameters in the rat

Indian Journal of Physiology and Pharmacology

Volumn 53, Issue 3, 2009, Pages 209-218

  Nsimba, S E D ^a  

^a Muhimbili University College of Health and Allied Sciences (MUHAS)   (South Africa)

Author keywords

Catalepsy locomotor activity; Chlorpromazine; Extrapyramidal effects; Neuroleptic; Stereotyped behaviours

Indexed keywords

AMPHETAMINE; APOMORPHINE; CHLORPROMAZINE; DOPAMINE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; AMINO ACID RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CATALEPSY; CIRCLING BEHAVIOR; CONTROLLED STUDY; FLUID INTAKE; FOOD INTAKE; GROOMING; HYPERACTIVITY; LOCOMOTION; MALE; MASTICATION; NONHUMAN; RAT; REARING; RECEPTOR UPREGULATION; STEREOTYPY; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; DRUG TOLERANCE; INTRAPERITONEAL DRUG ADMINISTRATION; MOTOR ACTIVITY; SPRAGUE DAWLEY RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CATALEPSY; CHLORPROMAZINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STEREOTYPED BEHAVIOR;

EID: 77950502682     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Denicker P. Discovery of the clinical use of neuroleptics. In: Discoveries in Pharmacology, Vol. 1: Psycho and Neuropharmacology, Eds, Parnham M. and Bruinvels J, Elsevier, Amsterdam, 1983; pp. 163-180.
2. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacol 1989; 99: 8118-8121.
3. Kane J, Dauphinais D, Barnes TRE, Alder LA, Rifkin A. "Assessing negative symptoms and extrapyramidal symptoms in schizophrenia": Workshop report. Psychopharmacol Bull 1993; 29: 45-49.
4. Den Boer JA, Ravelli DP, Huisman J, Ohrvik J, Verhoeven WMA, Westernberg HGM. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. Psychopharmacol 1991; 102: 76-84.
5. Wanibuchi F, Usuda S. Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacol 1990; 102: 339-342.
6. Ellenbroek B. Treatment of schizophrenia: a clinical and pre-clinical evaluation of neuroleptic drugs. Pharmacol & Ther 1993; 57: 1-78.
7. Chiodo L, Bunney R. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A 10 midbrain dopaminergic neurons. J Neurosci 1983; 5: 2539-2544.
8. White FJ, Wang RY. Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons in the rat. Life Sci 1983; 32: 983-993.
9. Puech AJ, Chermat A, Poncelet M, Doare L, Simon P. Antagonism of hypothermia and behavioural response to apomorphine: A simple, rapid and discriminating test for screening antidepressants and neuroleptics. Psychopharmacol 1981; 75: 84-91.
10. Creece I, Manian AA, Prosser TD, Synder SH. 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: Influence of chlorpromazine metabolites and derivatives. Eur J Pharmacol 1978; 47: 291-296.
11. Peroutka S, Synder S. Relationship of neuroleptic drug effects at dopamine, serotonin, a-adrenergic and histamine receptors to clinical potency. Am J Psych 1980; 137: 1518-1522.
12. Wadenberg M, Ahlenius S. Antipsychotic like profile of combined treatment with raclopride and 8-OH-DPA T in the rat: enhancement of antipsychotic like effects without catalepsy. J Neural Transm 1990; 83: 43-53.
13. Wingard LB, Brody TM, Larner J, Schwartz A. Physiology and biochemistry of the peripheral autonomic nervous system. In: Human Pharamacology, Molecular to Clinical 1991; pp. 77-113.
14. Theodorou A, Gommeren W, Clow A, Leysen J, Jenner P, Marsden CD. Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain. Life Sci 1981; 28: 1621-1627.
15. Christensen AV, Fjalland B, Moller Nilsen. On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacol 1976; 48: 1-6.
16. Rupiniak NMJ, Jenner P, Marsden CD. The effect of chronic neuroleptic administration on cerebral dopamine receptor function. Life Sci 1983; 32: 2289-2311.
17. Baldessarini RJ. Chemotherapy in Psychiatry. Havard University Press, Cambridge 1985.
18. Davis WM, Catravas JD, Waters IW. Effects of an I.V lethal dose of 3, 4- methylenedioxyamphetamine (MDA) in the dog and antagonism by chlorpromazine. Gen Pharmacol 1986; 2: 179-183.
19. Seeman P, Sellers EM, Roschlau WHE. Principles of Medical Pharmacology 3rd Edition, NOV, 1979, Toronto-Canada.
20. Leysen JE, Gommeren W, Laduron PM. Spiperone: A ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding. Biochem Pharmacol 1978; 27: 307-316.
21. Leysen JE, Nimegeers CJE, Tollenaere JP, Laduron PM. Serotonergic component of neuroleptic receptors. Nature 1978; 272: 168-171.
22. Salamone JD, Zigmond MJ, Stricker EM. Characterisation of the impaired feeding behaviour in rats given haloperidol or dopamine depleting brain lesions. Neurosci 1990; 39: 17-24.
23. Lawson WB, Roy S, Parent M, Herrera J, Karson C, Bigelow L. Fluid intake patterns in schizophrenia and normal controls. Prog Neuro- Psychopharmacol Biol Psychiat 1992; 16: 39-44.
24. Ellison G. Spontaneous orofascial movements in rodents induced by long term neuroleptic administration: a second opinion. Psychopharmacol 1991; 104: 404-108.
25. Leonard BE. Fundamentals of Psychopharmacology. Published by John Wiley & Sons, U.K. 1992; pp. 123-143.
26. Fibiger HC, Carter DA, Philips AG. Decreased intracranial self stimulation after neuroleptics or 6-hydroxydopamine: evidence for mediation by motor deficits rather than by reduced reward. Psychopharmacol 1976; 47: 21-27.
27. Rupiniak NMJ, Jenner P, Marsden CD. Cholinergic modulation of perioral behaviour induced by chronic neuroleptic administration to rats. Psychopharmacol 1983; 79: 226-230.
28. Constentin J, Marcais H, Portais P, Schwartz JC. Tolerance to hypolinesia elicited by dopamine agonists in mice: Hyposensitization of autoreceptors? Life Sci 1977; 20: 883-886.
29. Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psych 1978; 135: 164-173.
30. Creese I, Hamblin MW, Left SE, Sibley DR. CNS dopamine receptors. In: Iversen LL, Iversen SD, Solomon SH (eds). Handbook of psychopharmacology, Vol. 176, Biochemical studies of CNS receptors. New York: Plenum Press, 1983.
31. Muller P, Seeman P. Dopaminergic supersensitivity after neuropleptics: Time course and specificity. Psychopharmacol 1978; 60: 1-11.
32. Mattingly BA, Gotsick JE, Salamanca K. Latent sensitization to apomorphine following repeated low doses. Behav Neurosci 1988; 102: 553-558.
33. Cools AR. Two functionally and pharmacologically distinct receptors in the rat brain. Adv Biochem Psychopharmacol 1977a; 16: 215-225.
34. Cools AR. The influence of neuroleptics on central dopaminergic systems. In: Neurotransmission and disturbed behaviour. H. M. Van Praag and J. Bruinvels (eds), Bohn, Scheltma and Holkema 1977b; 73-96.
35. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol 1963; 20: 140-143.
36. Rastozi RB, Singhal RL, Lapiere YD. Effects of short-term and long-term neuroleptic treatment on brain serotonin synthesis and turnover: Focus on the serotonin hypothesis of schizophrenia. Life Sci 1981; 29: 735-741.
37. Snell LD, Johnson KM. Antagonism of N-methyl- D-aspertate induced transmitter release in the rat striatum by phencyclidine like dugs and its relationship to turning behaviour. J Pharmacol & Exp Ther 1985; 235: 50-57.
38. Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Furekawa H, Kamayama T. Serotonergic involvement in phencyclidine induced behaviours. Pharmacology, Biochemistry & Behaviour 1983; 21: 401-408.
39. Tiedtke P, Bischoff C, Schmidt WJ. MK-801 induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 1990; 81: 173-182.
40. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP 'nave direct effects on the dopamine D-2 and serotonin 5-HT-2 receptors; implications for models of schizophrenia. Mol Psychiat 2002; 7: 837-844.
41. Cho AK, Hiramatsu M, Pechnick RP, DiStefano E. Pharmacokinetic and pharmacodynamic evaluation of phencyclidine and its decadeutero variant. J Pharmacol & Exp Ther 1989; 250: 210-215.
42. Freed JW. An hypothesis regarding the antipsychotic effect of neuroleptic drugs. Pharmacol Biochem & Behav 1988; 32: 337-345.
43. Catravas JD, Waters I, Hickenbottom JP, Davis WM. The effects of haloperidol, chlopromazine and propranolol on acute amphetamine poisoning in conscious dog. J Pharmacol & Exp Ther 1977; 202: 230-243.
44. Nash JF, Meltzer HY, Gudelsky GA. Antagonism of serotonin receptor mediated neuroendocrine and temperature responses by atypical neuroleptics in the rat. Euro J Pharmacol 1988; 151: 463-469.
45. Cultler NR, Post RM, Bunney WE. Apomorphine hypothermia: An index of central dopamine receptor function in man. Comm Psychopharmacol 1979; 3: 375-380.
46. Bourin M. It is possible to predict the activity of new antidepressant in animals with simple psychopharmacological test? Fund Clin Pharmacol 1990; 4: 49-64.
47. Salmi P, Jimenez P, Ahlenius S. Evidence for specific involvement of dopamine 0-1 and 0-2 receptors in regulation of body temperature in the rat. Eur J Pharmacol 1993; 236: 395-400.